WuXi Biologics
8
29M
5
0.89
0.25
1
- Areas of investment
Summary
The main department of described Corporate Investor is located in the Wuxi. The fund was located in Asia if to be more exact in China.
Among the various public portfolio startups of the fund, we may underline Duoning Biotech, Inhibrx We can highlight the next thriving fund investment areas, such as Health Care, Biotechnology. Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund. For fund there is a match between the location of its establishment and the land of its numerous investments - China.
The usual cause for the fund is to invest in rounds with 4 partakers. The meaningful sponsors for the fund in investment in the same round are Viking Global Investors, RA Capital Management, Lilly Asia Ventures.
The fund is constantly included in 2-6 investment rounds annually. The top activity for fund was in 2019. Deals in the range of 10 - 50 millions dollars are the general things for fund.
Investments analytics
Analytics
- Total investments
- 8
- Lead investments
- 0
- Exits
- 1
- Rounds per year
- 0.89
- Follow on index
- 0.25
- Investments by industry
- Biotechnology (7)
- Therapeutics (3)
- Biopharma (3)
- Medical (3)
- Veterinary (2) Show 1 more
- Investments by region
-
- China (4)
- United States (3)
- Peak activity year
- 2019
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 6
- Group Appearance index
- 1.00
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Innolake Biopharm | 05 Jun 2023 | Biotechnology, Medical, Therapeutics | Early Stage Venture | 15M | Hangzhou, Zhejiang, China |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.